Paula Rodríguez-Otero, MD, PhD

Paula Rodríguez-Otero, MD, PhD, talks about promising phase 3 trials investigating combination treatments that include lenalidomide or daratumumab

The LINKER-SMM1 trial shows promising results for linvoseltamab in treating high-risk smoldering multiple myeloma with a favorable safety profile, notes Paula Rodríguez-Otero, MD, PhD.

The LINKER-SMM1 trial evaluates linvoseltamab's safety and efficacy in high-risk smoldering multiple myeloma, aiming to delay disease progression.